Identity & clonality
Keep construct, well, image and lineage evidence attached to the candidate throughout screening and expansion.
Cell line development.
Configure and run CLD protocols in Seal for screening, expansion and stability studies. Keep clone identity and lineage with every execution. Use neil to help configure studies, compare candidates and prepare selection reviews.
Configure your CLD workflow
A protocol for every stage of CLD.
Run screening, expansion and stability protocols in Seal. Capture clone identity, passage, samples and observations through the work, with the lineage carried into the next experiment.
Passage stability study
- Identify the clone and passage
- Record the culture and collect samples
- Link productivity and quality results
CL-19 / passage 30
- Candidate
- CL-19
- Planned passage
- 30
- Later titre
- Not recorded
Later-passage evidence outstanding
Configure with neil. Test with your team. Reuse the protocol.
Each run keeps its own values, evidence and history.
Choose with more than titre.
Compare early and later passages before taking a candidate forward.
Titre across passages
Passage 10Passage 30
Inspect the study records
UP-08 v02 · 15 mL fed-batch · passages 10 and 30. Titre method TTR-02 v03; early-harvest SEC method SEC-04 v02.
| Record | Clone | Early / late titre | Early SEC monomer |
|---|---|---|---|
| CLD-031 | CL-07 | 3.8 / 3.6 g/L | 98.8% |
| CLD-032 | CL-12 | 4.6 / 3.2 g/L | 97.1% |
| CLD-033 | CL-19 | 4.2 / Missing g/L | 99% |
One observation per displayed condition, not replicate means. Other quality attributes and clonality evidence are not supplied. The later result for CL-19 has not been reported.
Which clones deserve the next study?
neil
The highest titre is not the whole answer.
The highest early titre falls at the later passage. Check the culture records and repeat evidence before attributing the difference to stability.
CL-12: 30.4% lower titre at passage 30
Read the draft selection assessment
Keep three candidates in the review.
CL-07 has the smallest observed titre difference. CL-12 starts higher but drops at passage 30. CL-19 is incomplete. These observations do not establish a lead clone.
Before advancing a candidate
- Review matched culture conditions and replicate evidence for the passage comparison.
- Complete the product-quality panel and later-passage result for CL-19.
- Review clonality, lineage and stability evidence against the program’s selection criteria.
Draft based on CLD-031–033. No clone is selected or bank released by this example.
From the first candidate
to the cell bank.
Keep the complete selection history—not only the winning clone.
Screening & quality
Compare productivity with growth, viability and product-quality results. Expose missing tests and differences in methods.
Stability & selection
Bring passage studies, replicate evidence and program criteria into a reviewable selection assessment.
Banking & handoff
Carry the selected lineage, characterization and restrictions into bank records and the upstream development program.
Keep screening data
connected to the decision.
Start with imaging and screening files, culture observations and analytical results. Use exports or scope a permitted connection to the systems your team already runs.
Explore connectionsThen develop the culture process.
Clone selection and upstream process development are different jobs. Give the upstream team the selected cell source and its supporting evidence, then develop media, feeds and culture conditions.
Explore upstream process developmentQuestions from CLD teams.
Yes. Configure reusable protocols with instructions, fields, calculations, linked samples and review steps. Each execution retains the version used, recorded values, observations and results. neil can help prepare the configuration and analyse the resulting evidence; your team tests the workflow and defines the review and approval requirements for its intended use.
CLD evaluates and selects the biological candidate using lineage, clonality, productivity, quality and stability evidence. Upstream process development then establishes how to culture that cell line or strain: media, feeds, control strategy and scale-up. The records connect, but the decisions are distinct.
Your scientists make that decision. neil can assemble a comparison, expose missing or non-comparable results and draft the selection assessment. Titre alone does not establish stability, clonality, product quality or suitability for manufacturing.
Start with exports or scope a permitted connection to your imaging, screening, bioreactor, historian and analytical systems. Preserve candidate and sample identities, units, timestamps and method versions. Availability depends on the source interfaces; this example is not a live instrument connection.
Keep bank and vial identity, passage history, seed expansion, media and feed versions with each culture. Compare actual process conditions and analytical results across studies. Fed-batch and perfusion studies have different calculation and time-window requirements; the comparison must retain those differences.
The chosen recipe, material definitions, parameter rationale, scale assumptions and supporting studies can become a reviewable transfer package. Receiving equipment, local conditions and verification remain explicit work; matching setpoints do not establish scale equivalence.
These are fictional day-14 fed-batch observations under recipe UP-08 v02 at a 15 mL working volume. Early and late refer to passages 10 and 30. Each displayed titre is one reported observation, not a replicate mean. SEC monomer results are from early-passage harvests only. The example does not supply a full quality panel, clonality evidence or a completed stability assessment.